-
公开(公告)号：US20080248105A1
公开(公告)日：2008-10-09
申请号：US12105482
申请日：2008-04-18
Applicant: Datong Tang , Guoyou Xu , Yonghua Gai , Zhe Wang , Yat Sun Or , Hui-Yin Li
Inventor： Datong Tang , Guoyou Xu , Yonghua Gai , Zhe Wang , Yat Sun Or , Hui-Yin Li
IPC: A61K9/48 , C07H17/08 , A61K9/12 , A61P29/00 , A61K31/7052
CPC classification number: C07H17/08
Abstract: The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.
Abstract translation: 本发明包括具有不同物理性质的EP-13420多晶型形式：I型，II型，Ia型和一水合物和无定型EP-13420。 在本发明的另一个实施方案中，提供了以纯形式或彼此组合生产各种多晶形式的方法。 本发明还提供药物组合物和制剂，其包含多形态和无定形形式以及通过将药物组合物施用于需要这种治疗的受试者来治疗细菌感染的方法。
-
公开(公告)号：US20080187516A1
公开(公告)日：2008-08-07
申请号：US12016631
申请日：2008-01-18
Applicant: Ying Sun , Yat Sun Or , Zhe Wang
Inventor： Ying Sun , Yat Sun Or , Zhe Wang
IPC: A61K38/21 , A61K31/4015 , A61P31/12
CPC classification number: C07D487/04 , A61K31/4015 , C07D207/16 , C07K5/0808 , C07K5/0812
Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US07407942B2
公开(公告)日：2008-08-05
申请号：US11435401
申请日：2006-05-16
Applicant: Yat Sun Or , Deqiang Niu , Zhe Wang
Inventor： Yat Sun Or , Deqiang Niu , Zhe Wang
CPC classification number: C07H17/08
Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
Abstract translation: 本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。
-
公开(公告)号：US20080181868A1
公开(公告)日：2008-07-31
申请号：US12016643
申请日：2008-01-18
Applicant: Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
Inventor： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC: A61K31/407 , A61K38/21 , A61P31/12
CPC classification number: C07K5/0804 , C07K5/0812 , C07K7/06
Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07384921B2
公开(公告)日：2008-06-10
申请号：US11057476
申请日：2005-02-14
Applicant: Datong Tang , Guoyou Xu , Yonghua Gai , Zhe Wang , Yat Sun Or , Hui-Yin Li
Inventor： Datong Tang , Guoyou Xu , Yonghua Gai , Zhe Wang , Yat Sun Or , Hui-Yin Li
CPC classification number: C07H17/08
Abstract: The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.
Abstract translation: 本发明包括具有不同物理性质的EP-13420多晶型形式：I型，II型，Ia型和一水合物和无定型EP-13420。 在本发明的另一个实施方案中，提供了以纯形式或彼此组合生产各种多晶形式的方法。 本发明还提供药物组合物和制剂，其包含多形态和无定形形式以及通过将药物组合物施用于需要这种治疗的受试者来治疗细菌感染的方法。
-
Patent Agency Ranking
公开(公告)号：US20080032936A1
公开(公告)日：2008-02-07
申请号：US11499917
申请日：2006-08-04
Applicant: Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
Inventor： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
CPC classification number: C07K5/0808 , A61K38/00
Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20080008681A1
公开(公告)日：2008-01-10
申请号：US11768712
申请日：2007-06-26
Applicant: Deqiang Niu , Dong Liu , Joel Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
Inventor： Deqiang Niu , Dong Liu , Joel Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC: A61K38/21 , A61K31/498 , A61P31/12 , C07D245/04
CPC classification number: C07D245/04 , A61K38/212 , A61K38/215 , C07D403/12 , A61K2300/00
Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07265094B2
公开(公告)日：2007-09-04
申请号：US11031465
申请日：2005-01-07
Applicant: Yao-Ling Qiu , Deqiang Niu , Zhe Wang , Ly Tam Phan , Yat Sun Or
Inventor： Yao-Ling Qiu , Deqiang Niu , Zhe Wang , Ly Tam Phan , Yat Sun Or
CPC classification number: C07H17/08
Abstract: The present invention discloses compounds of formula I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
Abstract translation: 本发明公开了式I，II，III或IV的化合物或其外消旋物，对映异构体，区域异构体，盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。
-
公开(公告)号：US20070021330A1
公开(公告)日：2007-01-25
申请号：US10561718
申请日：2004-05-19
Applicant: Frank Wu , Suanne Nakajima , Yat Or , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Zhe Wang
Inventor： Frank Wu , Suanne Nakajima , Yat Or , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Zhe Wang
IPC: A61K38/12 , C07K5/12 , A61K31/4709
CPC classification number: C07K5/06139 , A61K38/00 , C07K5/06165
Abstract: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式（I）化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20060252713A1
公开(公告)日：2006-11-09
申请号：US11416739
申请日：2006-05-03
Applicant: Yonghua Gai , Datong Tang , Ying Sun , Zhigang Chen , Yat Or , Zhe Wang
Inventor： Yonghua Gai , Datong Tang , Ying Sun , Zhigang Chen , Yat Or , Zhe Wang
IPC: A61K31/7048 , C07H17/08
CPC classification number: C07H17/08
Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
224
records
(took 0.042 seconds)
